+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Toxoplasma Gondii Recombinant Antigen Market - Global Forecast 2026-2032- Product Image
Toxoplasma Gondii Recombinant Antigen Market - Global Forecast 2026-2032- Product Image
Sale

Toxoplasma Gondii Recombinant Antigen Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6080705
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Toxoplasma Gondii Recombinant Antigen Market is projected to reach USD 367.37 Million in 2026. It is expected to continue growing at a CAGR of 6.54%, reaching USD 537.00 Million by 2032.

Toxoplasma Gondii Recombinant Antigen: Executive Overview

Toxoplasma gondii recombinant antigens are engineered proteins used in serological assays, assay development, quality-control materials, and research related to toxoplasmosis. Their value lies in improved antigen definition, reproducibility, and suitability for standardized immunoassay formats compared with less-characterized antigen preparations. Demand is shaped by diagnostic quality requirements, congenital-infection screening, immunocompromised-patient management, food-safety research, and laboratory-method development. Interpretation should distinguish research-use applications from regulated clinical diagnostic use, because performance, validation, and regulatory expectations differ substantially.

Diagnostic Standardization and Multiplex Testing Are Reshaping Antigen Use

The landscape is shifting toward recombinant proteins with documented sequence identity, purity, lot consistency, and reproducible antibody-binding characteristics. Laboratories and assay developers increasingly emphasize analytical sensitivity, specificity, cross-reactivity assessment, and traceable quality systems. Multiplex serology, automated platforms, and confirmatory workflows are also encouraging antigen panels that can differentiate immune-response profiles more effectively than single-analyte approaches. At the same time, demand remains sensitive to regulatory classification, specimen diversity, regional strain variation, and the need to validate performance across pregnancy, congenital infection, immunosuppression, and general-population testing contexts.

Artificial Intelligence Accelerates Antigen Design, Validation, and Interpretation

Artificial intelligence can support epitope prioritization, protein-structure analysis, sequence comparison, and prediction of antibody-binding regions, helping researchers focus experimental work on candidates with stronger diagnostic rationale. Machine-learning tools can also assist image and signal interpretation, anomaly detection in assay runs, and integration of serology with clinical or epidemiological data. These benefits do not remove the need for wet-laboratory validation: predicted epitopes may not reflect native folding, post-translational effects, or population-specific immune responses. Responsible adoption therefore requires curated datasets, transparent performance measures, bias assessment, cybersecurity controls, and human review before clinical or public-health use.

Regional Insights: Regulation, Screening Priorities, and Laboratory Capacity Diverge

North America combines advanced laboratory infrastructure with strong expectations for analytical validation, quality documentation, and clinical-use compliance. Europe emphasizes harmonized regulatory practices, laboratory accreditation, and prenatal and congenital-infection considerations, while national testing pathways may still differ. Asia-Pacific presents substantial diversity: technologically advanced systems coexist with expanding laboratory capacity and varied exposure patterns, creating demand for adaptable assays and locally relevant validation. Latin America continues to prioritize access, maternal and congenital-health applications, and testing approaches suitable for uneven infrastructure. The Middle East is influenced by specialized hospital laboratories, cross-border care, and differing screening practices. Africa’s needs are closely tied to affordable, robust testing, infectious-disease integration, and strengthening of laboratory networks; performance evidence from local populations is especially important across all regions.

Group Insights: Economic and Security Alliances Shape Collaboration Priorities

ASEAN countries may benefit from interoperable laboratory protocols, regional proficiency testing, and supply arrangements that accommodate varied regulatory maturity. BRICS members represent diverse scientific and manufacturing capabilities, making collaboration on validation standards, reference materials, and technology transfer potentially valuable. The European Union supports alignment through shared regulatory principles and cross-border laboratory cooperation, while national implementation remains relevant. G7 members generally emphasize advanced assay development, robust evidence generation, and resilient supply chains. GCC states are likely to focus on centralized laboratory capability, specialist healthcare services, and procurement reliability. NATO members have an interest in continuity of diagnostic capacity, biosafety, and resilient laboratory logistics, although these priorities do not replace country-specific public-health requirements.

Country Insights: National Screening Systems and Research Capacity Set the Pace

Australia combines strong laboratory governance with geographically dispersed service delivery, making validated and transport-stable assays useful. Brazil’s priorities include maternal health, regional access, and locally relevant performance evaluation. Canada emphasizes quality systems, public-health coordination, and service coverage across large distances. China has substantial research and laboratory capacity alongside varied regional implementation needs. France, Germany, Italy, and Spain operate within European regulatory structures while retaining distinct clinical pathways and laboratory practices. India’s scale and diversity increase the importance of affordability, decentralized testing, and validation across heterogeneous settings. Japan and South Korea bring advanced laboratory capabilities and strong quality expectations. Mexico faces a continuing need to connect specialist testing with broader access and maternal-health programs. Russia’s requirements reflect national laboratory systems and local regulatory processes. The United Kingdom places emphasis on evidence-based testing pathways, laboratory quality, and specialized clinical services. The United States combines extensive research activity with demanding validation, compliance, and decentralized laboratory-market requirements.

Industry Priorities: Build Evidence, Resilience, and Responsible Automation

Industry leaders should first define the intended use-research, screening support, or clinical diagnosis-and align antigen selection, documentation, and validation accordingly. They should characterize sequence, purity, folding, stability, lot comparability, and cross-reactivity using panels that reflect target populations and clinically relevant conditions. A portfolio approach can reduce dependence on one antigen by combining complementary targets and, where appropriate, multiplex formats. Leaders should establish dual-source or geographically diversified supply for critical inputs, maintain change-control discipline, and use quality agreements with suppliers. Artificial intelligence should be deployed as a decision-support capability with documented datasets, reproducibility checks, and expert oversight. Finally, partnerships with reference laboratories and public-health stakeholders can improve external validation, proficiency testing, and adoption confidence.

Research Methodology: Evidence-Based Interpretation of the Antigen Landscape

This executive summary applies a structured qualitative approach grounded in the supplied market definition and established scientific, diagnostic, regulatory, and public-health considerations surrounding Toxoplasma gondii recombinant antigens. The analysis separates technology attributes from application requirements and considers differences in laboratory capacity, screening priorities, validation expectations, and regulatory context across the required regions, groups, and countries. It avoids unsupported numerical claims and does not infer commercial performance from geography alone. Findings should be tested against current peer-reviewed studies, regulatory guidance, laboratory standards, assay-validation data, procurement records, and country-specific epidemiological evidence before being used for investment, product, or clinical decisions.

Conclusion: Reproducibility and Contextual Validation Will Define Progress

Toxoplasma gondii recombinant antigens are positioned at the intersection of diagnostic standardization, maternal and congenital-health needs, immunocompromised-patient care, and laboratory research. The strongest opportunities are associated with well-characterized proteins, transparent validation, fit-for-purpose assay design, and reliable access across different health-system environments. Artificial intelligence can accelerate discovery and interpretation, but it must complement-not replace-experimental evidence and clinical oversight. Success will depend on combining technical quality with regional adaptability, resilient supply, responsible data use, and clear differentiation between research and regulated diagnostic applications.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Toxoplasma Gondii Recombinant Antigen Market, by Product Type
7.1. Introduction
7.2. ELISA Kit
7.2.1. IgG Detection
7.2.2. IgM Detection
7.3. Rapid Test Kit
7.3.1. Dipstick Test
7.3.2. Lateral Flow Immunoassay
7.4. Western Blot Kit
8. Toxoplasma Gondii Recombinant Antigen Market, by Technology
8.1. Introduction
8.2. Enzyme Linked Immunosorbent Assay
8.3. Immunochromatographic Assay
8.4. Polymerase Chain Reaction
8.5. Western Blot Assay
9. Toxoplasma Gondii Recombinant Antigen Market, by End User
9.1. Introduction
9.2. Academic Institutes
9.3. Diagnostic Laboratories
9.4. Hospitals
9.5. Pharmaceutical Companies
9.6. Research Institutes
10. Toxoplasma Gondii Recombinant Antigen Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. Toxoplasma Gondii Recombinant Antigen Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. Toxoplasma Gondii Recombinant Antigen Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Abbott Laboratories
14.2. Abcam plc
14.3. Bio-Rad Laboratories, Inc.
14.4. Bio-Techne Corporation
14.5. BioVenic
14.6. Creative BioMart Inc.
14.7. Creative Diagnostics Inc.
14.8. F. Hoffmann-La Roche Ltd
14.9. GenScript Biotech Corporation
14.10. Leinco Technologies, Inc.
14.11. Medix Biochemica Oy
14.12. Merck KGaA
14.13. Meridian Bioscience, Inc.
14.14. QED Bioscience Inc.
14.15. QIAGEN N.V.
14.16. RayBiotech, Inc.
14.17. Rekom Biotech S.L.
14.18. SERION Immunologics
14.19. The Native Antigen Company Ltd.
14.20. Thermo Fisher Scientific, Inc.
14.21. ViroGen Corporation
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global Toxoplasma Gondii Recombinant Antigen Market, Years Considered for the Study
FIGURE 2. Global Toxoplasma Gondii Recombinant Antigen Market, Research Design
FIGURE 3. Global Toxoplasma Gondii Recombinant Antigen Market, Research Framework
FIGURE 4. Global Toxoplasma Gondii Recombinant Antigen Market, Data Triangulation
FIGURE 5. Global Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Toxoplasma Gondii Recombinant Antigen Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Toxoplasma Gondii Recombinant Antigen Market Segmentation & Coverage
TABLE 2. Global Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 3. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global ELISA Kit Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global ELISA Kit Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global ELISA Kit Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global IgG Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global IgG Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global IgG Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global IgM Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global IgM Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global IgM Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Rapid Test Kit Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Rapid Test Kit Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Rapid Test Kit Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Dipstick Test Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Dipstick Test Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Dipstick Test Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Lateral Flow Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Lateral Flow Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Lateral Flow Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Western Blot Kit Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Western Blot Kit Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Western Blot Kit Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 26. Global Enzyme Linked Immunosorbent Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Enzyme Linked Immunosorbent Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Enzyme Linked Immunosorbent Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Immunochromatographic Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Immunochromatographic Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Immunochromatographic Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Western Blot Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Western Blot Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Western Blot Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 39. Global Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. North America Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 63. North America Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 64. North America Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 65. North America Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 66. North America Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 69. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 70. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 71. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 72. Latin America Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 76. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 77. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 78. Europe Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 81. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 82. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 83. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 84. Middle East Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 88. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 89. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 90. Africa Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 94. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 95. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 96. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 97. ASEAN Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 100. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 101. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 102. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 103. GCC Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 107. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 108. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 109. European Union Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 113. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 114. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 115. BRICS Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 118. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 119. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 120. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 121. G7 Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 125. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 126. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 127. NATO Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Global Toxoplasma Gondii Recombinant Antigen Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. United States Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 130. United States Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. United States Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 132. United States Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 133. United States Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 134. United States Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Canada Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 136. Canada Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. Canada Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 138. Canada Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 139. Canada Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 140. Canada Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 142. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 143. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 144. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 145. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 146. Mexico Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 148. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 150. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 151. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 152. Brazil Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 154. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 156. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 157. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 158. United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Germany Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 160. Germany Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 161. Germany Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 162. Germany Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 163. Germany Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 164. Germany Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. France Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 166. France Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. France Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 168. France Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 169. France Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 170. France Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Russia Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 172. Russia Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Russia Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 174. Russia Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 175. Russia Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 176. Russia Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Italy Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 178. Italy Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 179. Italy Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 180. Italy Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 181. Italy Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 182. Italy Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Spain Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 184. Spain Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. Spain Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 186. Spain Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 187. Spain Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 188. Spain Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. China Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 190. China Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 191. China Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 192. China Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 193. China Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 194. China Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. India Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 196. India Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 197. India Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 198. India Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 199. India Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 200. India Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Japan Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 202. Japan Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 203. Japan Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 204. Japan Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 205. Japan Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 206. Japan Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. Australia Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 208. Australia Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 209. Australia Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 210. Australia Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 211. Australia Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 212. Australia Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, 2017-2032 (USD Million)
TABLE 214. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 215. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, by ELISA Kit, 2017-2032 (USD Million)
TABLE 216. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, by Rapid Test Kit, 2017-2032 (USD Million)
TABLE 217. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, by Technology, 2017-2032 (USD Million)
TABLE 218. South Korea Toxoplasma Gondii Recombinant Antigen Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Global Toxoplasma Gondii Recombinant Antigen Market Share, by Key Player, 2025
TABLE 220. Global Toxoplasma Gondii Recombinant Antigen Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • Abcam plc
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • BioVenic
  • Creative BioMart Inc.
  • Creative Diagnostics Inc.
  • F. Hoffmann-La Roche Ltd
  • GenScript Biotech Corporation
  • Leinco Technologies, Inc.
  • Medix Biochemica Oy
  • Merck KGaA
  • Meridian Bioscience, Inc.
  • QED Bioscience Inc.
  • QIAGEN N.V.
  • RayBiotech, Inc.
  • Rekom Biotech S.L.
  • SERION Immunologics
  • The Native Antigen Company Ltd.
  • Thermo Fisher Scientific, Inc.
  • ViroGen Corporation

Related Topics

Related Reports

Diagnostic Substances Market - Global Forecast 2026-2032 - Product Image

Diagnostic Substances Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Diagnostic Specialty Antibodies Market - Global Forecast 2026-2032 - Product Image

Diagnostic Specialty Antibodies Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Diagnostic Specialty Antibodies - Global Strategic Business Report - Product Image

Diagnostic Specialty Antibodies - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Diagnostic Specialty Antibodies Market Report 2026 - Product Image

Diagnostic Specialty Antibodies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Prostate Specific Antigen (PSA) Test Market Report 2026 - Product Image

Prostate Specific Antigen (PSA) Test Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.